Abstract: Objective  To explore the efficacy of Xuebijing injection combined with ulinastatin in the treatment of acute respiratory distress syndrome (ARDS) induced by sepsis. Methods  A total of 60 patients with ARDS induced by sepsis from May 2014 to July 2016 were randomly divided into  observation group (n=30)  and control group(n=30). The patients in control group were treated with ulinastatin, and those in observation group were treated with Xuebijing on the basis of control group. The SOFA score and the APACHE Ⅱ score were used to analyze and compare the test indexes and clinical efficacy of the two groups. Results  The PCT,  BNP and CRP in observation group were significantly lower than those in control group(P<0.05). The time of invasive ventilation and EICU in observation group were significantly shorter than that in control group. The 28day mortality rate in observation group were significantly lower than that of control group(3.3% vs 10.0%, P>0.05). There was no significant difference in hospitalization time in general  ward between two groups of  patients (P>0.05).Conclusion  Xuebijing combined with ulinastatin is effective in the treatment of patients with ARDS induced by sepsis. It reduces the incidence of complications and improves the cure rate of patients,  worth popularizing in clinical practice.

Key words: sepsis； ulinastatin, xuebijing, respiratory distress syndrome, , adult